Organon & Co.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Inventories
- Inventories
Inventories consisted of:
| ($ in millions) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Finished goods | $734 | $751 |
| Raw materials | 13 | 14 |
| Work in process | 800 | 791 |
| Supplies | 74 | 81 |
| Total (approximates current cost) | $1,621 | $1,637 |
| Increase (Decrease) to last in, first out (“LIFO”) costs | 4 | 5 |
| $1,625 | $1,642 | |
| Recognized as: | ||
| Inventories | $1,373 | $1,406 |
| Other assets | 252 | 236 |
| Inventories valued under the LIFO method | 135 | 114 |
In connection with the Jada divestiture in January 2026, $8 million of inventory was reclassified to Assets held for sale on the Consolidated Balance Sheet as of December 31, 2025.
As part of the Dermavant acquisition in 2024, the Company acquired $97 million of inventory, which included a $63 million purchase accounting inventory fair value adjustment. As of March 31, 2026 the amount has been fully amortized. As of December 31, 2025, there was $7 million remaining in inventory related to the fair value adjustment.
Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has long-term vendor supply contracts that include certain annual minimum purchase commitments.
-14-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.